Project 3: The AMPK Autophagy Pathway as a Metabolic Liability in Pancratic Ductal Adenocarcinoma
项目 3:AMPK 自噬途径作为胰腺导管腺癌的代谢负担
基本信息
- 批准号:10629065
- 负责人:
- 金额:$ 46.68万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-07-06 至 2028-06-30
- 项目状态:未结题
- 来源:
- 关键词:AddressAdenocarcinomaAffectAlanineAttenuatedAutomobile DrivingAutophagocytosisAutophagosomeBiochemicalBiological AvailabilityCell CompartmentationCell NucleusCell SurvivalCell physiologyCellsCharacteristicsChemoresistanceChloroquineClinicClinicalCollaborationsDNA DamageDesmoplasticDevelopmentDiseaseDisease ProgressionDuct (organ) structureEnzymesEpigenetic ProcessEpithelial CellsEpitheliumFRAP1 geneFibroblastsGene ExpressionGeneticGenetic TranscriptionGenetically Engineered MouseGrowthHDAC3 geneHistone DeacetylaseHumanKPC modelKnowledgeLesionMEK inhibitionMEKsMalignant NeoplasmsMalignant neoplasm of pancreasMeasuresMediatingMediatorMetabolicMetabolic stressMetabolismModalityMusMutationMyelogenousNormal CellNutrientNutrient availabilityOrganellesOrganoidsPancreas TransplantationPancreatic Ductal AdenocarcinomaParacrine CommunicationPathway interactionsPerformancePharmaceutical PreparationsPhenotypePhosphorylationPhosphotransferasesPopulationProteinsRecyclingRegulationReporterReportingResearchResistanceRoleSignal TransductionSourceStressStromal CellsTherapeuticToxic effectTranslatingUp-RegulationVascularizationWorkXenograft procedureantagonistcheckpoint inhibitionchemotherapydefined contributioneffective therapyefficacy evaluationepigenetic regulationexperimental studyin vivoinhibition of autophagyinhibitorkinase inhibitormTOR inhibitionmouse modelneoplastic cellnovelnovel strategiespancreatic ductal adenocarcinoma modelpancreatic neoplasmpharmacologicprogramsresponsesynergismtargeted treatmenttherapeutic targettherapy resistanttooltranscriptional reprogrammingtreatment responsetreatment strategytumortumor growthtumor microenvironmenttumor progression
项目摘要
PROJECT SUMMARY – Project 3: Autophagy
Pancreatic ductal adenocarcinoma (PDA) is one of the deadliest forms of cancer with few effective therapies.
The poor performance of current treatments is partly due to metabolic adaptations in both the tumor and stromal
compartments, such as the recycling of proteins and organelles through increased autophagy. As a hallmark of
PDA, autophagy provides a key source of nutrients in the restrictive tumor microenvironment (TME).
Accumulating evidence also implicates the autophagy program as a critical mediator of resistance to numerous
therapeutics, including chemotherapy, MEK inhibitors, and immune checkpoint inhibition. Foundational research
from the Shaw group decoded key biochemical steps involved in the initiation of autophagy, including upstream
regulation of AMPK and its downstream activation of ULK1 and ULK2, the kinases that drive autophagosome
formation. More recent work from the Shaw group has also revealed that AMPK can block the translocation of
Class II HDACs to the nucleus. Despites these advances, the specific roles of AMPK in autophagy control and
epigenetic regulation have never been investigated in pancreatic cancer. Moreover, while autophagy has
emerged as an attractive therapeutic target in pancreatic cancer, efforts to translate this to the clinic have been
hindered by a lack of autophagy-specific inhibitors, with only broad lysosomotropic agents like chloroquine
available for study. To address this gap, the lab has developed novel, bioavailable inhibitors of ULK1 and ULK2,
two of only three druggable enzymes specific to the autophagy pathway. These inhibitors provide critical tools
with which to dissect the contributions of autophagy to PDA growth and form the basis for a new approach for
overcoming therapeutic resistance in this deadly disease. Here, experiments proposed in Aim 1 will define when
and where different facets of AMPK signaling and autophagy are activated during disease progression in the
autochthonous mouse KPC model of PDA. In collaboration with Project 1, conditional deletions of AMPK or its
downstream targets ULK1/2 and HDAC3 will be used to evaluate their contribution to metabolic adaptations
driving tumor growth and epigenetic changes mediating tumor cellular functions. In addition, the contribution of
AMPK pathway components in supporting PDA resistance to chemotherapeutics and targeted therapies will be
dissected. In Aim 2, the roles of canonical and noncanonical autophagy in non-cell autonomous support of
pancreatic tumor growth will be delineated by comparing stromal deletion of ULK1/2 and ATG7. In addition,
experiments will dissect cell-specific requirements for autophagy within the fibroblast and myeloid compartments
in supporting PDA therapeutic resistance. In Aim 3, the Shaw lab’s novel, bioavailable ULK inhibitor will be used
to determine how selective inhibition of autophagy impacts PDA growth through reprogrammed tumor and
stromal cell function. The potential of ULK inhibitors in rescuing autophagy-dependent therapeutic resistance to
chemotherapies, MEK inhibitors, and immune checkpoint inhibition will be explored.
项目摘要-项目3:自噬
胰腺导管腺癌(PDA)是最致命的癌症之一,几乎没有有效的治疗方法。
目前治疗效果不佳的部分原因是肿瘤和间质的代谢适应。
隔室,如通过增加自噬的蛋白质和细胞器的循环。作为…的标志
自噬在限制性肿瘤微环境(TME)中提供了一个关键的营养来源。
越来越多的证据还表明,自噬程序是抵抗众多
治疗,包括化疗、MEK抑制剂和免疫检查点抑制。基础研究
从Shaw研究小组解码了启动自噬的关键生化步骤,包括上游
AMPK的调节及其驱动自噬小体的ULK1和ULK2的下游激活
队形。Shaw研究小组的最新研究也表明,AMPK可以阻止
第二类高密度脂蛋白到细胞核。无视这些进展,AMPK在自噬控制和
表观遗传调控在胰腺癌中从未被研究过。此外,虽然自噬已经
作为胰腺癌的一个有吸引力的治疗靶点,将其转化为临床的努力
由于缺乏自噬特异性抑制物,只有氯喹等广泛的溶酶体促进剂
可供学习。为了弥补这一差距,该实验室开发了ULK1和ULK2的新型生物可用抑制剂,
仅有的三种针对自噬途径的可用药酶中的两种。这些抑制剂提供了关键的工具
在此基础上,剖析自噬对PDA生长的贡献,并形成一种新的方法
克服这种致命疾病的治疗耐药性。在这里,目标1中提出的实验将定义何时
在疾病进展过程中,AMPK信号和自噬的不同方面被激活
自体小鼠PDA KPC模型。与项目1合作,有条件地删除AMPK或其
下游指标ULK1/2和HDAC3将用于评估它们对代谢适应的贡献
推动肿瘤生长和表观遗传学变化,介导肿瘤细胞功能。此外,中国的贡献
支持PDA对化疗药物和靶向治疗耐药的AMPK通路组件将
被解剖了。在目标2中,典型和非典型自噬在非细胞自主性支持中的作用
胰腺肿瘤的生长将通过比较ULK1/2和ATG7的间质缺失来描述。此外,
实验将剖析成纤维细胞和髓系细胞内自噬的特定细胞要求。
在支持PDA治疗耐药方面。在Aim 3中,将使用Shaw实验室的新型生物可用ULK抑制剂
为了确定选择性抑制自噬如何通过重新编程的肿瘤和
基质细胞功能。ULK抑制剂在挽救自噬依赖的治疗耐药中的潜力
将探索化疗、MEK抑制剂和免疫检查点抑制。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Reuben Shaw其他文献
Reuben Shaw的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Reuben Shaw', 18)}}的其他基金
Decoding And Targeting The LKB1-AMPK Signaling Pathway In Cancer
解码并靶向癌症中的 LKB1-AMPK 信号通路
- 批准号:
10667573 - 财政年份:2017
- 资助金额:
$ 46.68万 - 项目类别:
Decoding And Targeting The LKB1-AMPK Signaling Pathway In Cancer
解码并靶向癌症中的 LKB1-AMPK 信号通路
- 批准号:
10448279 - 财政年份:2017
- 资助金额:
$ 46.68万 - 项目类别:
Decoding And Targeting The LKB1-AMPK Signaling Pathway In Cancer
解码并靶向癌症中的 LKB1-AMPK 信号通路
- 批准号:
10222594 - 财政年份:2017
- 资助金额:
$ 46.68万 - 项目类别:
AMPK and AMPK-related kinases in lung cancer development and treatment
AMPK 和 AMPK 相关激酶在肺癌发生和治疗中的作用
- 批准号:
8605862 - 财政年份:2013
- 资助金额:
$ 46.68万 - 项目类别:
AMPK and AMPK-related kinases in lung cancer development and treatment
AMPK 和 AMPK 相关激酶在肺癌发生和治疗中的作用
- 批准号:
8785659 - 财政年份:2013
- 资助金额:
$ 46.68万 - 项目类别:
AMPK and AMPK-related kinases in lung cancer development and treatment
AMPK 和 AMPK 相关激酶在肺癌发生和治疗中的作用
- 批准号:
8420203 - 财政年份:2013
- 资助金额:
$ 46.68万 - 项目类别:
AMPK and AMPK-related kinases in lung cancer development and treatment
AMPK 和 AMPK 相关激酶在肺癌发生和治疗中的作用
- 批准号:
9186506 - 财政年份:2013
- 资助金额:
$ 46.68万 - 项目类别:
AMPK and AMPK-related kinases in lung cancer development and treatment
AMPK 和 AMPK 相关激酶在肺癌发生和治疗中的作用
- 批准号:
8984294 - 财政年份:2013
- 资助金额:
$ 46.68万 - 项目类别:
Role of LKB1 and AMPK in Metformin and TZD Control of Glucose Metabolism in Liver
LKB1 和 AMPK 在二甲双胍和 TZD 控制肝脏葡萄糖代谢中的作用
- 批准号:
7353028 - 财政年份:2007
- 资助金额:
$ 46.68万 - 项目类别:
相似国自然基金
大肠癌发生机制的adenoma-adenocarcinoma pathway同serrated pathway的关系的研究
- 批准号:30840003
- 批准年份:2008
- 资助金额:12.0 万元
- 项目类别:专项基金项目
相似海外基金
Synergistic Radiosensitization of Hypoxic Pancreatic Adenocarcinoma using Gd-Texaphyrin Oxygen-Loaded Nanodroplets
使用 Gd-Texaphyrin 载氧纳米液滴对缺氧胰腺腺癌进行协同放射增敏
- 批准号:
478914 - 财政年份:2023
- 资助金额:
$ 46.68万 - 项目类别:
Operating Grants
Expression mechanism of immune checkpoint molecules after carbon-ion radiotherapy in cervical adenocarcinoma specimens
宫颈腺癌碳离子放疗后免疫检查点分子的表达机制
- 批准号:
23K14913 - 财政年份:2023
- 资助金额:
$ 46.68万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Study of fibrosis in pancreatic ductal adenocarcinoma (PDAC) and application of adipose-derived stromal/stem cells for PDAC treatment
胰腺导管腺癌(PDAC)纤维化的研究以及脂肪源性基质/干细胞在 PDAC 治疗中的应用
- 批准号:
23K15035 - 财政年份:2023
- 资助金额:
$ 46.68万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
IRAK4 AS A NOVEL IMMUNOTHERAPEUTIC TARGET IN PANCREATIC DUCTAL ADENOCARCINOMA
IRAK4 作为胰腺导管腺癌的新型免疫治疗靶点
- 批准号:
10442874 - 财政年份:2023
- 资助金额:
$ 46.68万 - 项目类别:
Therapeutic Targeting of NSD2 in Lung Adenocarcinoma
NSD2 在肺腺癌中的治疗靶向
- 批准号:
10657069 - 财政年份:2023
- 资助金额:
$ 46.68万 - 项目类别:
Control mechanisms of lung adenocarcinoma by SGLT2 inhibitors for treating diabetes mellitus.
SGLT2抑制剂治疗糖尿病对肺腺癌的控制机制。
- 批准号:
23K08326 - 财政年份:2023
- 资助金额:
$ 46.68万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Establishment of histological transformation model from lung small cell carcinoma from adenocarcinoma to explore the therapeutic strategies of small cell lung carcinoma.
建立肺小细胞癌腺癌组织学转化模型,探讨小细胞肺癌的治疗策略。
- 批准号:
23K14614 - 财政年份:2023
- 资助金额:
$ 46.68万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms of tumor progression controlled by tumor-initiating cells and cancer-associated fibroblasts in pancreatic adenocarcinoma.
阐明胰腺腺癌中肿瘤起始细胞和癌症相关成纤维细胞控制的肿瘤进展机制。
- 批准号:
23K15075 - 财政年份:2023
- 资助金额:
$ 46.68万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Molecular mechanisms for development of pulmonary invasive mucinous adenocarcinoma
肺浸润性粘液腺癌发生的分子机制
- 批准号:
23H02698 - 财政年份:2023
- 资助金额:
$ 46.68万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Elucidating the Cellular Origins of lung adenocarcinoma
阐明肺腺癌的细胞起源
- 批准号:
10743611 - 财政年份:2023
- 资助金额:
$ 46.68万 - 项目类别: